Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg)
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Safety
Conditions
Safety, Pharmacokinetics, Healthy Subjects
Trial Timeline
Nov 16, 2015 → May 25, 2016
NCT ID
NCT02601625About Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg)
Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg) is a phase 1 stage product being developed by AstraZeneca for Safety. The current trial status is completed. This product is registered under clinical trial identifier NCT02601625. Target conditions include Safety, Pharmacokinetics, Healthy Subjects.
What happened to similar drugs?
3 of 4 similar drugs in Safety were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02601625 | Phase 1 | Completed |
Competing Products
20 competing products in Safety